Breaking |

Breaking |

Covid-19 vaccine Zydus Cadila get DCGI nod for human clinical trials
Published : Jul 3, 2020, 12:53 pm IST
Updated : Jul 3, 2020, 12:53 pm IST
SHARE ARTICLE
Covid-19 vaccine
Covid-19 vaccine

A potential Covid-19 vaccine indigenously developed by the Ahmedabad-based Zydus Cadila Healthcare Ltd has got the nod

New Delhi: A potential Covid-19 vaccine indigenously developed by the Ahmedabad-based Zydus Cadila Healthcare Ltd has got the nod from the Drugs Controller General of India (DCGI) for human clinical trials.

CoronavirusCoronavirus

Advertisement

The approval process was fast-tracked following recommendation by the subject expert committee on Covid-19.

The assent for human trials was given after the company submitted data of clinical trial on animals to the DCGI in which the vaccine candidate was found to be successful with respect to safety, the source said.

CoronavirusCoronavirusThe phase I and II trials will take around three months to be completed, as per the sources.

Advertisement

The country's 'first' indigenous COVID-19 vaccine candidate Covaxin, developed by Hyderabad-based Bharat Biotech in collaboration with the Indian Council of Medical Research and National Institute of Virology (NIV), had recently got the nod for human clinical trials from the DCGI.

SHARE ARTICLE

ROZANA SPOKESMAN

Advertisement
Advertisement

Sensational Revelations: Jasbir Singh Exposed as Pakistani Spy — What Greed Drove His Betrayal?

08 Jun 2025 11:06 AM

Girl blackmails gym boy with obscene video after befriending him at gym

08 Jun 2025 11:03 AM

Lavish Oberoi Case: Cricketer Abhishek Sharma\'s brother-in-law | Lavish Oberoi Interview

08 Jun 2025 10:59 AM

Government is strict, no mercy for spies; 800 bloggers on radar, 8 arrested on espionage charges

06 Jun 2025 6:19 PM

Amit Arora’s Big Statement Against Bhindranwale: Amit Arora spoke harshly about Jarnail Bhindranwale

06 Jun 2025 6:16 PM

Russia-Ukraine War: Russia retaliates Ukraine, fires multiple missiles and drones, several killed

06 Jun 2025 6:13 PM
Advertisement